Volume 7, Number 7—June 2001
International Conference on Emerging Infectious Diseases 2000
Conference Panel Summary
Institutional Review Boards: Developing Countries Consideration
Highlight and copy the desired format.
|EID||Pape J. Institutional Review Boards: Developing Countries Consideration. Emerg Infect Dis. 2001;7(7):547. https://dx.doi.org/10.3201/eid0707.017726|
|AMA||Pape J. Institutional Review Boards: Developing Countries Consideration. Emerging Infectious Diseases. 2001;7(7):547. doi:10.3201/eid0707.017726.|
|APA||Pape, J. (2001). Institutional Review Boards: Developing Countries Consideration. Emerging Infectious Diseases, 7(7), 547. https://dx.doi.org/10.3201/eid0707.017726.|
Institutional review boards (IRBs) play an essential role in protecting the rights of volunteers involved in research projects. Their function has become more complex, particularly concerning projects conducted in developing countries. But can IRBs in the United States guarantee the protection of human subjects involved in research projects in developing countries?
IRBs have no effective way of controlling what goes on in the field. The complex ethical clearance process does not determine whether persons engaged in research projects in developing countries are fully aware of the major aspects of the studies they participate in. The clearance process includes the IRB approval and consent forms. Required U.S. consent forms are too long and the language too complicated to be certain all participants have a full understanding of the study. The forms also appear to be intended more to offer legal protection to sponsoring agencies than to protect the welfare of the volunteer. Most importantly, the forms do not guarantee that volunteers have fully understood the objectives, risks, and benefits of the study, and the extent of their voluntary participation. To protect volunteers as well as all persons and institutions involved, these forms must not only communicate necessary information concerning the study to be conducted but also evaluate volunteers' knowledge and their desire to participate. To achieve this goal, we propose to use a simple questionnaire administered by a team not involved in the volunteer recruitment process. We have used such a questionnaire to evaluate potential volunteers for a phase II HIV vaccine trial. Although volunteers had three intensive, 2-hour counseling sessions, only half responded correctly to all 21 questions. The others were referred for additional counseling and reevaluation.
The IRB process requires that collaborative projects with U.S. institutions have clearance from multiple IRBs. Each IRB meets generally once a month and uses its own consent forms. Each has its own set of rules. Each will respond with different concerns that must be addressed. The approval process may create a lag time of 3 to 12 months to obtain ethical clearances for a project lasting 12 to 24 months.
The ethical clearance process can be simplified in several ways: 1) All studies supported by NIH should have a unique IRB application form and a unique IRB consent form. 2) A certain percentage of the research grant should be allocated to support the ethical clearance process. Ethical support should be available at the grant's initiation. 3) While waiting for the formal ethical clearance and final consent, potential volunteers could be counseled and evaluated. 4) The primary responsibility of local and national IRBs should be clearly determined. IRBs must share responsibilities to achieve the greatest benefit for volunteers. 5) A mechanism must be developed to resolve conflicts between IRBs from developed and developing countries. Yearly meetings of IRBs from host and sponsoring institutions should take place to facilitate the exchange of documents and other information.Cite This Article
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 27, 2012
- Page last updated: April 27, 2012
- Page last reviewed: April 27, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)